

Effectiveness of Radiotherapy for Elderly Patients with Grade III Anaplastic Astrocytoma

Chirag G. Patil MD MS; Kristen Nosova M.B.A.; Debraj Mukherjee MD, MPH; Maxwell Boakye MD; Amin Mirhadi; Shivanand P. Lad MD PhD; Behrooz Hakimian MD; Keith L. Black MD; Miriam Nuno PhD

Department of Neurosurgery, Cedars-Sinai Medical Center



Introduction

Radiation is utilized routinely in the management of anaplastic astrocytoma (AA). However, the role of radiation therapy (RT) in the optimal management of elderly patients with Grade III, AA remains controversial. We used the SEER cancer registry to evaluate the effectiveness of RT in elderly AA patients.

Methods

Surveillance, Epidemiology, and End Results (SEER) registry was used to query a total of 489 patients over 70 years of age diagnosed with histology confirmed Grade III, AA between 1973 -2005. Overall survival was evaluated using the Kaplan-Meier method.

Multivariate analysis was performed.

	Tumor Type					
Variables	Astrocytoma (N=388)	Ependymoma (N=2)	Oligodendroglioma (N=58)	Ganglioglioma (N=2)	p value	
Age at diagnosis					.32	
mean (SD)	76.8 (4.5)	79.0 (9.9)	76.9 (4.9)	82.5 (4.9)		
median	76.0	79.0	76.0	82.5		
Gender					.66	
male	193 (49.7)	1 (50.0)	34 (58.6)	1 (50.0)		
female	195 (50.3)	1 (50.0)	24 (41.4)	1 (50.0)		
Race, N (%)					.98	
White	354 (91.2)	2 (100.0)	57 (98.3)	2 (100.0)		
Black	11 (2.8)	0(0)	1 (1.7)	0(0)		
Other	23 (6.0)	0(0)	0 (0)	0(0)		
Tumor size, N (%)					.07	
≥ 4 mm	268 (85.9)	2 (100.0)	39 (95.1)	0(0)		
< 4 mm	44 (14.1)	0 (0)	2 (4.9)	1 (100.0)		
Vital Status, N (%)					.09	
alive	11 (2.8)	0(0)	2 (3.5)	1 (50.0)		
deceased	377 (97.2)	2 (100.0)	56 (96.6)	1 (50.0)		
Radiotherapy, N (%)					.95	
radiation	250 (64.4)	1 (50.0)	39 (67.2)	1 (50.0)		
no radiation	138 (35.6)	1 (50.0)	19 (32.8)	1 (50.0)		
Surgery, N (%)					<.0001	
biopsy	203 (52.3)	0 (0)	24 (41.4)	0(0)		
gross total resection	44 (11.3)	1 (50.0)	10 (17.2)	0(0)		
partial resection	37 (9.5)	1 (50.0)	21 (36.2)	1 (50.0)		
surgery, NOS	104 (26.8)	0 (0)	3 (5.2)	1 (50.0)		
Treatment type, N (%)					.95	
surgery only	138 (35.6)	1 (50.0)	19 (32.8)	1 (50.0)		
surgery + radiation	250 (64.4)	1 (50.0)	39 (67.2)	1 (50.0)		

	Tumor type				
	AA (N=388)	AO (N=58)	AA and AO (N=446)		
Median Survival in months*	4 (3, 4)	7 (5, 10)	4 (4, 5)		
Overall survival rate, % (95% CI)					
6 month	38.3 (33.4, 43.1)	62.1 (48.3, 73.1)	41.4 (36.8, 46.0)		
12 month	19.3 (15.5, 23.4)	34.5 (22.6, 46.7)	21.3 (17.6, 25.2)		
18 month	9.3 (6.6, 12.4)	21.8 (12.2, 33.2)	10.9 (8.2, 14.0)		
24 month	5.2 (3.3, 7.8)	9.1 (3.4, 18.3)	5.7 (3.8, 8.2)		
36 month	3.5 (2.0, 5.8)	7.3 (2.3, 16.0)	4.0 (2.4, 6.2)		

Results

Among the 489 elderly patients with AA, 62% received radiation and 60% underwent surgical resection as part of their initial treatment. 38% of patients underwent surgery plus RT, 24% had RT only, 23% had surgery only and 15% had no treatment. Median survival for patients who underwent RT plus surgery was 6 months while patients who did not receive surgery or RT survived only 2 months. In comparison, the surgery only cohort had survival of 3 months and the RT only group had median survival of 4 months. Patients who received RT as part of their initial treatment had significantly longer survival than patients who did not receive RT (5 months vs. 3 months p<0.0001). Multivariate analysis showed that radiotherapy significantly improved overall survival (hazard ratio [HR 0.63], 95% confidence interval [CI: 0.52-0.76), p<.0001) after adjusting for extent of resection, age, and year of diagnosis. Patients over 70 years of age were less likely to receive RT than younger patients (62% vs. 80%, p<0.001).


for cerebellar patients accor-		ledian survival				
	AA	p value	AO	p value	All AA	p value
Tumor size		24		66		43
≥ 4 mm	4 (3, 4)		7 (3, 12)		4(3, 5)	
< 4 mm	5 (3, 9)		8 (2, 14)		5 (3, 9)	
Radiotherapy		<.0001		.05		<.0001
radiation	5 (4, 6)		8 (6, 13)		6 (5, 7)	
no radiation	2(2, 3)		3 (2, 6)		2(2, 3)	
Extent of Surgery*		.008		.65	(0) (0)	.001
high resection	60 10		10 0 10		7.5 (4,	
low resection	6 (3, 10) 4 (3, 4)		10 (3, 15) 6 (5, 9)		11) 4 (3, 5)	
Treatment type	4 (3, 4)	<.0001	6 (5, 9)	.05	4 (3, 3)	<.0001
surgery only	2 (2, 3)	<.0001	3 (2, 6)	.03	2 (2, 3)	<.000
surgery + radiation	5 (4, 6)		8 (6, 13)		6 (5, 7)	
Γable 4. Multivariate an	alysis of cancer	-specific sur	vival using (Cox propo	rtional	
* Low-resection corresponds t Table 4. Multivariate an hazard model for 388 Az Characteristics	alysis of cancer	-specific sur	vival using (1111	rtional 6 CI	p value
Table 4. Multivariate an hazard model for 388 A. Characteristics	alysis of cancer	-specific sur		1111	MANUFESTAL.	p value
Table 4. Multivariate an	alysis of cancer	-specific sur	HR	959	6 CI	
Table 4. Multivariate an hazard model for 388 A. Characteristics Tumor type (ref: AO) AA	alysis of cancer	-specific sur		959	MANUFESTAL.	p value
Table 4. Multivariate an hazard model for 388 Az Characteristics Tumor type (ref: AO) AA Gender (ref: male)	alysis of cancer	-specific sur	HR 1.41	959	6 CI 1.97	.05
Table 4. Multivariate an hazard model for 388 Az Characteristics Tumor type (ref: AO) AA Gender (ref: male) female	alysis of cancer	-specific sur	HR	959	6 CI	
Table 4. Multivariate an hazard model for 388 A. Characteristics Tumor type (ref: AO) AA Gender (ref: male) female Race (ref: Caucasian)	alysis of cancer	-specific sur	HR 1.41 0.75	959 1.0, 0.60	6 CI 1.97	.05
Table 4. Multivariate an hazard model for 388 Az Characteristics Tumor type (ref: AO) AA Gender (ref: male)	alysis of cancer	-specific sur	HR 1.41	959 1.0, 0.60	6 CI 1.97	.05
Table 4. Multivariate an hazard model for 388 A. Characteristics Tumor type (ref: AO) AA Gender (ref: male) female Race (ref: Caucasian)	alysis of cancer	-specific sur	HR 1.41 0.75	959 1.0, 0.60 0.48	6 CI 1.97 1-0.93	.05
Table 4. Multivariate an nazard model for 388 A. Characteristics Tumor type (ref: AO) AA Gender (ref: male) female Race (ref: Caucasian) African American Other*	alysis of cancer A and 58 AO pa	-specific sur	HR 1.41 0.75 0.98	959 1.0, 0.60 0.48	6 CI 1.97 -0.93	.05
Table 4. Multivariate an nazard model for 388 A. Characteristics Tumor type (ref: AO) AA Gender (ref: male) female Race (ref: Caucasian) African American Other*	alysis of cancer A and 58 AO pa	-specific sur	HR 1.41 0.75 0.98	959 1.0, 0.60 0.48 0.34	6 CI 1.97 -0.93	.05
Table 4. Multivariate an hazard model for 388 AJ Characteristics Tumor type (ref: AO) AA Gender (ref: male) female Race (ref: Caucasian) African American Other* Tumor size (ref: ≥ 4 mm < 4 mm	alysis of cancer A and 58 AO p	-specific sur	HR 1.41 0.75 0.98 0.57	959 1.0, 0.60 0.48 0.34	6 CI 1.97 1-0.93 1-1.98 1-0.93	.05 .008 .94 .03
Table 4. Multivariate an hazard model for 388 A./ Characteristics Tumor type (ref: AO) AA Gender (ref: male) female Race (ref: Caucasian) African American Other* Tumor size (ref: ≥ 4 mm	alysis of cancer A and 58 AO p	-specific sur	HR 1.41 0.75 0.98 0.57	95% 1.0, 0.60 0.48 0.34	6 CI 1.97 1-0.93 1-1.98 1-0.93	.05 .008 .94 .03
Table 4. Multivariate an hazard model for 388 AJ. Characteristics Tumor type (ref: AO) AA Gender (ref: male) female Race (ref: Caucasian) African American Other* Tumor size (ref: ≥ 4 mm < 4 mm Radiotherapy (ref: no rac	alysis of cancer A and 58 AO pr	-specific sur	HR 1.41 0.75 0.98 0.57	95% 1.0, 0.60 0.48 0.34	6 CI 1.97 -0.93 -1.98 -0.93	.05 .008 .94 .03

Learning Objectives

IR: Hazard Ratio, CI: Confidence Interval

By the conclusion of this session participants should be able to:

- 1. Discuss the survival outcomes of elderly anaplastic astrocytoma patients.
- 2.Describe the effect of radiotherapy on outcomes of patients with anaplastic astrocytoma.
- 3. Describe the utilization of radiotherapy in the elderly AA patients as compared to younger AA patients.



Conclusions

Elderly patients with Anaplastic Astrocytoma who underwent RT as part of their initial treatment had better overall survival compared to patients who did not receive RT.

Figure 3. Overall survival for 442 grade III patients (AA, AO). Kaplan-Meier c

